CASE REPORT

Beta-propeller protein-associated neurodegeneration: a case report and review of the literature

Kjersti Eline Stige¹, Ivar Otto Gjerde¹, Gunnar Houge³, Per Morten Knappskog³,⁴ & Charalampos Tzoulis¹,²

¹Department of Neurology, Haukeland University Hospital, Bergen, Norway
²Department of Clinical Medicine, University of Bergen, Bergen, Norway
³Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
⁴Department of Clinical Science, K.G. Jebsen Centre for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway

Correspondence
Charalampos Tzoulis, Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway.
Tel: +4755975045; Fax: +4755975164;
E-mail: charalampos.tzoulis@nevro.uib.no

Funding Information
This work was supported by grants from the Regional Health Authority of Western Norway (Helse Vest, grants no 911903, 911988, and 911810).

Received: 21 October 2017; Revised: 27 November 2017; Accepted: 6 December 2017

Clinical Case Reports 2018; 6(2): 353–362
doi: 10.1002/ccr3.1358

Introduction

Beta-propeller protein-associated neurodegeneration (BPAN) was first described by Haack et al. in 2012 [1]. Before the elucidation of its genetic etiology, the disorder was termed static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). This term reflected the disorder’s typical clinical course, comprising static psychomotor retardation in childhood followed by progressive deterioration in adolescence or young adulthood with progressive dystonia, parkinsonism, and dementia. After the discovery of pathogenic mutations in the WDR45 gene, the disorder was renamed BPAN in keeping with the naming conventions of other forms of neurodegeneration with brain iron accumulation (NBIA).

Beta-propeller protein-associated neurodegeneration is a rare disease. NBIA disorders have a prevalence of 1/1,000,000, and of these, BPAN constitutes only 7% [2]. Since 2012, 68 cases of BPAN have been reported in PubMed, but systematic epidemiological studies are lacking and the true incidence and prevalence remain therefore unknown. The aim of this article was to provide an overview of BPAN focusing on clinical history, genetics, and pathophysiology. Patient management will not be discussed in detail as this was recently published elsewhere [3].

Methods

Case report

To illustrate the typical history and clinical phenotype of BPAN, we present a case that was recently diagnosed at our hospital. This patient is, to our knowledge, the first published case of BPAN in Scandinavia.
Literature review

A systematic PubMed search was performed until 23 June 2017 using the following keywords: “BPAN,” “beta-propeller protein-associated neurodegeneration,” and “WDR45.” A total of 42 articles were retrieved and evaluated by the authors. A total of 34 articles contained information on case reports, of which five were excluded because they were not available in the English language (n = 1), provided limited clinical information (n = 2), or were not possible to obtain (n = 2).

Case Report

A 33-year-old woman of Norwegian descent was referred for neurological evaluation due to rapid motor deterioration. Her parents and two brothers were healthy (Fig. 1). She had been born after a normal pregnancy and delivery and had an uncomplicated neonatal and early development until the age of 6 months, when she was admitted due to episodic cyanosis and eye-rolling/deviation raising suspicion about epileptic seizures. The parents reported persistent crying and intermittent fever during the weeks prior to admittance. Electroencephalography (EEG) showed high-voltage activity with bursts of spike and wave activity, similar to that seen in children with infantile spasms. Suspicion of viral encephalitis was raised, but CSF examination was unremarkable. After discharge, the patient continued having complex partial seizures, characterized by automatisms in the form of lip-smacking and swallowing, which later converted to short pure consciousness lapses, similar to absence seizures. Interictal EEG continued to show epileptic activity of variable localization. Computed tomography (CT) of the brain showed generalized cerebral atrophy.

Her early motor development was normal. She walked at 13 months and was able to climb as a child. At 18 months, it was noted that her language and cognitive development were delayed. At 2.5 years of age, she lost her speech with the exception of a few words and communicated mostly by inarticulate sounds. Intermittent strabismus was described during her school years, and occlusion therapy was attempted but was unsuccessful due to poor compliance. Her hearing developed normally. She was treated with salivary gland surgery at the age of seven due to drooling. Concentration difficulties, anxiety, and phobias were also reported.

The patient’s epilepsy responded to treatment with phenobarbital, but due to side effects, she was switched to carbamazepine and finally valproic acid, which was well tolerated and provided optimal long-term seizure control. Her antiepileptic therapy was discontinued at the age of 12, as she had become seizure free. At the age of 17, she developed myoclonic jerks, particularly in her upper extremities, which improved after initiation of clonazepam. Magnetic resonance imaging (MRI) showed signs of metal accumulation in the basal ganglia with conspicuously low T2 signal in the basal ganglia. Susceptibility-weighted imaging (SWI) was not performed.

At the age of 32, her motor function began deteriorating. She developed flexion of her left elbow, wrist, and fingers. This was followed by rapid worsening of general

Figure 1. The pedigree structure of the Norwegian family; the affected individual is shown as a filled symbol and is marked with an arrow.
locomotion and gait with frequent falls. Her cognitive and language skills also declined further, and she developed urinary and fecal incontinence. On clinical examination, she was obese, short in stature, but with a generally “happy demeanor” and had severe intellectual disability and poor language skills. She had pronounced dystonic posturing and rigidity in all extremities, bradykinesia, freezing of gait, and stooped posture. Tendon reflexes were normal. She communicated mainly through inarticulate sounds and gestures. Dysmorphic features were noted in the form of short distal phalanx of the thumbs, enlarged gap between the upper teeth, and strabismus. MRI showed a hyperintense “halo” surrounding a band of central hypointensity in the substantia nigra and cerebral peduncles on T1-weighted images and hypointensity in the substantia nigra and globus pallidus (mostly pronounced in substantia nigra) on T2-weighted images. SWI showed prominent hypointensity consistent with metal deposition in the areas mentioned above. There was also marked cerebral atrophy and slight atrophy of vermis (Fig. 2).

Whole-exome sequencing (WES) was performed using the SeqCap EZ MedExome Target Enrichment System (Roche) and Illumina NextSeq 500 platform with NextSeq 500/550 High Output v2 kit (2 × 75 cycles). Data analysis was performed as previously described [4]. Variant filtering was carried out in the NGS module of Cartagenia. WES identified a heterozygous frameshift mutation in the

![Figure 2. MRI findings in BPAN. Brain MRI of the Norwegian patient at the age of 33 years, showing typical findings for BPAN. (A) Axial T1-weighted image at the level of the midbrain shows symmetric hyperintense “halos” surrounding a band of central hypointensity in the substantia nigra (arrows). Axial T2-weighted and SWI image of the same area shows prominent hypointensities in the substantia nigra and cerebral peduncles (arrows). (B) Axial images at the level of the striatum show high T1 signal and low T2 and SWI signal in the globus pallidus. The low SWI signal corresponds to areas of increased iron deposition (arrowheads).](image-url)
| PN    | Published in | S        | cDNA     | Protein     | I                      | L-dopa age | L-dopa Epilepsy | L-dopa Deterioration | Parkinsonism | Dystonia | Dysmorphia | PCD | L-dopa response | L-dopa dyskinesia |
|-------|--------------|----------|----------|-------------|------------------------|------------|----------------|----------------------|------------|----------|-------------|-----|----------------|----------------|
| 1     | Nishioka -15 | F        | c.969_970insT | p.Y324Cfs*18 | dn                     | 30         | -              | +                    | +          | +        | na          | +  | +             | +              |
| 2     | Nishioka -15 | F        | c.585_588delTA | p.I196fs*26 | dn                     | 37         | -              | +                    | +          | na       | +          | +  | +             | +              |
| 3     | Nishioka -15 | F        | c.414_419delGTGA | p.E138_F139del | dn                     | 36         | -              | 32                   | -          | na       | +          | +  | +             | +              |
| 4     | Nishioka -15 | F        | c.628T>C     | p.S210P     | na                     | 33         | -              | +                    | -          | +        | na          | +  | +             | -              |
| 5     | Nishioka -15 | F        | c.400C>T     | p.R134*     | na                     | 35         | -              | 34                   | -          | +        | +          | +  | -             | -              |
| 6     | Nishioka -15 | F        | c.587_588delTA | p.I196fs*26 | dn                     | 33         | -              | 28                   | +          | +        | na          | +  | +             | +              |
| 7     | Nishioka -15 | F        | c.293T>C     | p.L98P      | dn                     | 41         | -              | 39                   | -          | na       | +          | +  | -             | -              |
| 8     | Hayflick -13, Haack -12 | F    | c.1007_1008del | p.Y336Cfs*5 | dn                     | 23         | +              | +                    | na         | na       | +          | +  | +             | +              |
| 9     | Hayflick -13, Haack -12 | F    | c.38G>C      | p.R13P      | dn                     | 44         | -              | 26                   | +          | +        | +          | +  | +             | +              |
| 10    | Hayflick -13, Haack -12 | F    | c.1_5del     | p.M17       | na                     | 30         | +              | 26                   | +          | na       | +          | +  | +             | +              |
| 11    | Hayflick -13, Haack -12 | F    | c.293T>C     | p.L98P      | na                     | 29         | -              | +                    | +          | na       | +          | +  | +             | +              |
| 12    | Hayflick -13, Haack -12 | F    | c.476del     | p.L159Rfs*2 | na                     | 43         | -              | 26                   | +          | na       | +          | +  | +             | +              |
| 13    | Hayflick -13, Haack -12 | F    | c.19C>T      | p.R7*       | na                     | 34         | -              | 25                   | +          | na       | +          | +  | -             | +              |
| 14    | Hayflick -13, Haack -12 | F    | c.56-1G>A    | Splicing defect | na                 | 22         | +              | 15                   | +          | na       | +          | +  | +             | +              |
| 15    | Hayflick -13, Haack -12 | F    | c.700C>T     | p.R234*     | na                     | 39         | -              | 29                   | +          | na       | +          | +  | +             | +              |
| 16    | Hayflick -13, Haack -12 | F    | c.400C>T     | p.R134*     | dn                     | 49         | -              | 37                   | +          | +        | +          | +  | +             | +              |
| 17    | Hayflick -13, Haack -12 | M    | c.228_229del | p.E76Dfs*38 | dn                     | 37         | -              | 27                   | +          | +        | +          | +  | +             | +              |
| 18    | Hayflick -13, Haack -12 | F    | c.405_409del | p.K135Nfs*2 | na                     | 40         | -              | 30                   | +          | na       | +          | +  | +             | +              |
| 19    | Hayflick -13, Haack -12 | F    | c.359dup     | p.K121Ffs*18 | dn                     | 45         | -              | 31                   | +          | na       | +          | +  | +             | +              |
| 20    | Hayflick -13, Haack -12 | F    | c.830 + 1G>A | Splicing defect | dn                | 37         | +              | 26                   | +          | na       | +          | +  | +             | +              |
| 21    | Hayflick -13, Haack -12 | M    | c.19dup      | p.R7Pfs*64  | na                     | 31         | -              | 28                   | +          | na       | +          | +  | +             | +              |
| 22    | Hayflick -13, Haack -12 | F    | c.235 + 1G>A | Splicing defect | dn               | 35         | -              | 30                   | +          | na       | +          | +  | +             | +              |
| 23    | Hayflick -13, Haack -12 | F    | c.1007_1008del | p.Y336Cfs*5 | dn                     | 24         | -              | 19                   | +          | na       | +          | +  | +             | +              |
| 24    | Hayflick -13, Haack -12 | F    | c.694_703del | p.L232Afs*53 | dn                     | 44         | -              | 29                   | +          | na       | +          | +  | +             | +              |
| Paudel -15  |              |          |           |             |                        |            |                |                      |            |          |                  |    |
| 25    | Hayflick -13, Haack -12 | F    | c.183C>A     | p.N61K      | dn                     | 17         | +              | 16                   | +          | na       | +          | +  | +             | +              |
| 26    | Hayflick -13, Haack -12 | M    | c.1025_1034del | p.G342Dfs*12 | insACATATTT          | 31         | -              | 26                   | +          | +        | +          | +  | +             | +              |
| 27    | Hayflick -13, Haack -12 | F    | c.55 + 1G>C  | Splicing defect | dn                | 43         | +              | 25                   | +          | na       | +          | +  | +             | +              |
| 28    | Hayflick -13, Haack -12 | F    | c.830 + 1T>C | Splicing defect | dn               | 27         | -              | 20                   | +          | na       | +          | +  | +             | +              |
| 29    | Hayflick -13, Haack -12 | F    | c.1A>G       | Start codon  | aborted               | 31         | +              | 29                   | -          | na       | +          | +  | +             | +              |
| 30    | Hayflick -13, Haack -12 | F    | c.186delT    | p.L63Vfs*19 | na                     | 16         | +              | 15                   | na         | +        | +          | +  | +             | +              |
| 31    | Hoffjan -16  | F        | c.440-2A>G   | Splicing defect | dn                | 5          | +              | -                    | -          | +        | -          | +  | +             | -              |
| 32    | Verhoeven -14 | F    | c.622_663del | p.F221*     | dn                     | 33         | na              | na                   | 32         | -        | +          | +  | na           | +              |
| 33    | Verhoeven -14 | F    | c.752_754del | p.S251del   | na                     | 52         | na              | +                    | +          | -        | +          | +  | +             | -              |
| 34    | Verhoeven -14 | F    | c.1030del    | p.C344fs    | dn                     | 42         | na              | -                    | 33         | na       | +          | +  | +             | -              |
| 35    | Xixis -15    | F        | c.400C>T     | p.R134*     | dn                     | 6          | na              | -                    | na         | na       | na          | +  | +             | +              |
| 36    | Saitsu -13   | F        | c.439 + 1G>T | p.G147V;V147L148ins8 | dn        | 33         | na              | 26                   | +          | +        | na          | +  | +             | +              |

(Continued)
| PN       | Published in | S   | cDNA    | Protein       | Diagnosis age | LRF | Epilepsy age | Deterioration age | Parkinsonism | Dystonia | Dysmorphia | PCD | L-dopa response | L-dopa dyskinesia |
|----------|--------------|-----|---------|---------------|---------------|-----|--------------|-------------------|--------------|----------|------------|-----|----------------|------------------|
| 37       | Saitsu -13   | F   | c.516G>C | p.D174Gfs*29  | dn            | 28  | na           | +                 | 25           | +        | na         | na  | na            | na               |
| 38       | Saitsu -13   | F   | c.437dupA | p.L148fs*3   | na            | 40  | na           | +                 | 30           | +        | na         | na  | na            | na               |
| 39       | Saitsu -13   | F   | c.637C>T | p.Q213*      | na            | 51  | na           | +                 | 24           | na       | +          | na  | na            | na               |
| 40       | Saitsu -13   | F   | c.1033_ 1034dupAA | p.N345Kfs*67 | dn            | 33  | na           | +                 | 23           | +        | na         | na  | na            | na               |
| 41       | Takano -16,  | F   | c.813-1G>C | Splicing defect | dn            | 3   | +            | –                 | –            | –        | +          | no  | +            | na               |
|          | Morikawa -17 |     |         |               |               |     |              |                   |              |          |            |     |               |                  |
| 42       | Wynn -17     | F   | c.597_598delGT | p.L201Kfs*21 | dn            | 34  | na           | –                 | 32           | –        | +          | na  | na            | na               |
| 43       | Yoganathan -16 | F | c.400G>A | p.R134Ter     | dn            | 5   | +            | +                 | –            | –        | –          | –   | –            | na               |
| 44       | Long -15     | F   | c.251A>G | p.D84G        | dn            | 18  | –            | –                 | –            | –        | –          | –   | –            | no               |
| 45       | Zarate -16   | M   | c.161_163delTGG | p.V54del      | inh           | 20  | –            | na                | na           | +        | na         | na  | na            | na               |
| 46       | Zarate -16   | F   | c.161_163delTGG | p.V54del      | inh           | 14  | –            | –                 | na           | na       | +          | –   | na            | na               |
| 47       | Tsentscher -15 | F | c.626C>A | p.A209D       | dn            | 33  | na           | +                 | 27           | +        | +          | –   | na            | na               |
|          | Hattingen -17|     |         |               |               |     |              |                   |              |          |            |     |               |                  |
| 48       | Van Goethem -14 | F | c.488delC | p.P163Rfs*34  | dn            | na  | na           | +                 | 22           | –        | +          | na  | na            | na               |
| 49       | Okamoto -14  | F   | c.C868T  | p.Q290*       | dn            | 6   | +            | +                 | –            | –        | +          | –   | –            | na               |
| 50       | Ichinose -14 | F   | c.519 + 1_519 | Splicing defect | dn            | 31  | na           | –                 | 30           | +        | +          | na  | na            | +               |
|          |               |     |         |               |               |     |              |                   |              |          |            |     |               |                  |
| 51       | Ohba -14     | F   | c.830 + 1G>A | p.L278*       | dn            | 14  | +            | +                 | –            | –        | +          | –   | –            | na               |
| 52       | Ozawa -14    | F   | c.322del  | p.S108fs*10   | dn            | 39  | –            | +                 | 28           | +        | na         | +   | na            | na               |
| 53       | Khalifa -15  | F   | c.587-588del | p.V166fs      | dn            | 11  | +            | –                 | –            | –        | +          | –   | –            | na               |
| 54       | Rathore -14  | F   | c.342A>G  | p.A209D       | dn            | 15  | –            | –                 | 13           | –        | +          | na  | +            | +               |
| 55       | Abidi -16    | M   | Deletion of WDR45 | + 3del        | dn            | 43  | –            | +                 | –            | +        | na         | –   | na            | na               |
| 56       | Ryu -15      | F   | c.345_1G>A | r.345_439del | dn            | na  | –            | +                 | –            | +        | na         | na  | –            | na               |
| 57       | Spiegel -16  | M   | c.1007_1008delAT | p.Y336C*5    | dn            | na  | –            | –                 | –            | –        | –          | na  | –            | na               |
| 58       | Nakashima -16 | M  | c.131-1G>A | + 3del        | dn            | 1   | –            | –                 | –            | –        | –          | na  | –            | na               |
| 59       | Nakashima -16 | M  | c.248G>A | p.W83*        | dn            | 2   | +            | +                 | –            | –        | –          | na  | –            | na               |
| 60       | Nakashima -16 | M  | c.400C>T | p.R134*      | inh           | 7   | –            | +                 | –            | –        | –          | na  | –            | na               |
| 61       | Nakashima -16 | F   | c.400C>T | p.R134*      | inh           | 7   | na           | +                 | –            | –        | –          | –   | na            | na               |
| 62       | Araju -17    | F   | c.447_448del | p.C149*       | dn            | 8   | +            | +                 | –            | +        | na         | na  | na            | na               |
| 63       | Araju -17    | F   | c.447_448del | p.C149*       | dn            | 8   | +            | +                 | +            | +        | na         | na  | na            | na               |
| 64       | Our case     | F   | c.1007_1008delAT | p.Y336C*5    | dn            | 33  | –            | +                 | 32           | +        | +          | +   | +            | –               |

PN, patient number; S, sex; I, inheritance; RLF, Rett-like features; PCD, progressive cognitive decline; F, female; M, male; na, not available; dn, de novo; inh, inherited; +, yes; –, no.

ª 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

K. E. Stige et al. Beta-propeller protein-associated neurodegeneration
Beta-propeller protein-associated neurodegeneration

WDR45 gene: c.1007_1008del, p.Y336Cfs*5. This mutation has been previously reported in two patients with BPAN and is known to be pathogenic. The patient’s parents tested negative for the mutation consistent with a de novo origin. Based on these findings, the patient was diagnosed with BPAN. Treatment with levodopa/carbidopa (100/25 mg qid) led to substantial improvement in motor function (in particular, improvement of the bradykinesia), language skills (slight improvement of vocabulary), and her general condition.

Literature Review

Demographics and clinical spectrum of BPAN

A total of 64 patients were included in the analysis, comprising 55 women (85.9%) and nine men (14.1%) (Tables 1 and 2) [1, 5–32]. Mean age at diagnosis was 27.6 ± 14 years (range 1–52), and mean age at deterioration was 27.2 ± 5.7 (range 13–39). The origin of the mutations was assessed in 47 patients and found to be de novo in 43 (91.5%) and inherited in four (8.5%).

All patients had delayed psychomotor development and intellectual disability manifesting from infancy or early childhood characterized by pronounced loss of expressive language skills. In addition, 44 of 59 patients (74.6%) developed progressive cognitive decline upon reaching adolescence or early adulthood. The majority had epileptic seizures (42/62, 67.7%) and movement disorders including dystonia (44/60, 73.3%) and parkinsonism (35/58, 60.3%). Epileptic seizures started in early childhood and showed a spectrum ranging from focal to generalized seizures and epileptic spasms. Multiple seizure types were commonly seen in the same individuals [6, 16, 20]. The epilepsy was generally most severe in childhood and improved with advancing age [3]. Dystonia and parkinsonism developed in adolescence or early adulthood when the motor function started deteriorating and caused severe motor disability with many patients becoming wheelchair-dependent or bedridden.

Rett-like features, including developmental regression, loss of purposeful hand skills, stereotypic hand movements, and bruxism, were seen in 14 patients (14/50, 28%). All but one of these [23] had atypical Rett syndrome or Rett-like features, meaning that they did not fulfill all formal diagnostic criteria for Rett syndrome.

Spasticity, sleep disturbances, and ocular/visual defects have been variably reported to be a part of the phenotype. A systematic statistical evaluation of these was not possible due to inconsistent reporting and incomplete descriptions in the literature. Limb spasticity of highly variable severity has been described in both children and adults. A wide range of sleep disturbances has been reported including REM sleep disorder [18], excessive movement during sleep [18], circadian rhythm sleep disorder [18, 24], hypersomnia with choreiform movements at onset of sleep [18], parasomnia with nocturnal screaming [18], and unspecified sleep disorders [5, 18, 22]. Ocular/visual involvement has been reported in 17 patients and comprises myopia [7, 18, 22], astigmatism [18], strabismus [7, 26], abnormal pupillary shade [18], spontaneous retinal detachment [18], bilateral partial retinal coloboma [18], patchy loss of pupillary ruff [18], difficulties with eyesight with intermittent double-vision [18], bilateral optic disk pallor [24], bilateral optic atrophy [15, 24], increased visual evoked potential (VEP) latency [18], cortical blindness [16], and retinitis pigmentosa [6].

Dysmorphic features have not been systematically characterized in BPAN. Definite data were only available for 16 of 64 patients (25%) of whom 11 (68.8%) were reported to have dysmorphic features. These included microcephaly [25], abnormal nasal bridge (depressed, high, wide, and flat) [9, 26, 27, 30], a small mouth [26], tented upper lip [26], hypertelorism [9, 26], epicantal folds [9, 26], downslanting palpebral fissures [9, 27], large ears [26, 27], bilateral low-set ears [9], low hanging columella [27], short philtrum [9, 30], high palate [9],

| Feature                          | Number of Patients | Percentage |
|----------------------------------|-------------------|------------|
| Female                           | 55/64             | 85.9%      |
| Male                             | 9/64              | 14.1%      |
| De novo mutation                 | 43/47             | 91.5%      |
| Inherited mutation               | 4/47              | 8.5%       |
| Rett-like features               | 14/50             | 28%        |
| Epileptic seizures               | 42/62             | 67.7%      |
| Parkinsonism                     | 35/58             | 60.3%      |
| Dystonia                         | 44/60             | 73.3%      |
| Dysmorphic features              | 11/16             | 68.8%      |
| Progressive cognitive decline    | 44/59             | 74.6%      |
| L-dopa response                  | 22/23             | 95.7%      |
| L-dopa-induced dyskinesias       | 15/20             | 75%        |

n: number of patients with the feature/total evaluated.

Table 2. Summary of clinical features.

| Radiological findings                  | Number of Patients | Percentage |
|----------------------------------------|--------------------|------------|
| Iron deposition                        | 55/61              | 90.2%      |
| Cerebral atrophy                       | 44/63              | 69.8%      |
| Cerebellar atrophy                     | 17/63              | 27%        |
| Delayed myelination                    | 6/63               | 9.5%       |
| Thin corpus callosum                   | 2/63               | 3.2%       |
| Dilated ventricles                     | 2/63               | 3.2%       |

n: number of patients with the feature/total evaluated.

Table 3. Summary of radiological features.
downturned mouth and micrognathia [9], narrow face [30], narrow nose [30], thin upper lip [30], kyphosis [23], flat and almost rocker bottom feet [7], fingers tapered [7, 27] with fifth finger clinodactyly [7], partial synophrys [7], and congenital talipes varus [6]. Small cold hands and feet were also reported [23]. It was not possible to identify any common dysmorphic features from this analysis.

Other clinical features of BPAN include neuropsychiatric symptoms [18, 22, 24], “happy demeanor” [7], and excessive drooling [7, 25]. Chorea has been reported in one patient [12]. Bilateral sensory neural hearing loss has also been reported [15] as well as auditory agnosia [24].

**Imaging findings**

The vast majority of patients with BPAN (55/61, 90.2%) had MRI findings consistent with iron deposition in the basal ganglia. The two most typical findings were as follows:

- Hypointense signal in the *substantia nigra* and *globus pallidus* on T2-weighted or iron-sensitive sequences such as SWI. This finding was more prominent in older individuals. The T2 hypointensity was generally more pronounced in the *substantia nigra* compared to the *globus pallidus*, a feature that may help distinguish BPAN from other forms of NBIA.
- Hyperintense “halo” surrounding a band of central hypointensity in the *substantia nigra* and cerebral peduncles on T1-weighted images. This finding is generally regarded as pathognomonic for BPAN.

Other features included cerebral atrophy (44/64, 68.8%), cerebellar atrophy (17/64, 26.6%), delayed myelination [6, 9, 15, 26], thin corpus callosum [25, 26], and dilated ventricles [9, 10]. Radiological features are summarized in Table 3.

**Treatment**

Treatment with oral levodopa leads to clinical improvement in 20 of 21 (95.2%) of BPAN patients with parkinsonism. Positive effects included amelioration of rigidity and bradykinesia, improved affect, appetite, and interest in activities [14, 18, 21, 22]. Slight improvement of expressive language was seen in one case [14]. The majority of patients (15/20, 75%) also had treatment side effects, however, in the form of motor fluctuation and dyskinesias [18]. Clinical improvement was reported in two cases without parkinsonism. One of these experienced amelioration of dystonia, whereas the nature of improvement is not specified in the other. As seen in Table 2, several BPAN patients with parkinsonism (14/35, 40%) were either not treated with levodopa or no information was given on treatment effect.

**Pathophysiology**

BPAN is caused by mutations in the WDR45 gene. WDR45 encodes WIPI-4 (WD repeat domain phosphoinositide-interacting protein 4), which is part of the WD40 repeat protein family. This group of proteins facilitates the assembly of multiprotein complexes and is important in many essential biological processes, such as signal transduction, cell cycle progression, gene regulation, and apoptosis [33, 34]. WD40 domain-containing proteins assume a symmetric, seven-bladed, beta-propeller platform structure that supports protein–protein interactions. WIPI-4 is phylogenetically related to two yeast proteins (ATG18 and ATG21) that are part of a recycling system involved in transferring and recycling components from the isolation membrane (also known as phagophore) to the growing autophagosome [35, 36]. Available evidence suggests that human WIPI4 protein is involved in autophagy and interacts with the known autophagy factors ATG2A and ATG2B [3, 35, 36]. Patients with WDR45 mutations have lower autophagic activity and accumulation of aberrant early autophagic structures in lymphoblastoid cell lines (LCLs) [19]. These findings established a direct link between autophagy dysfunction and neurodegeneration in humans [19]. Research into the pathophysiology of BPAN could provide us with new insight into the role of autophagy in iron metabolism [37], and thus further increase our knowledge of pathophysiology of NBIA disorders as a whole. Currently, the primary pathophysiological process leading to NBIA disorders is still not fully understood. Whether abnormal iron deposition is a final common pathway causing disturbed neuronal dysfunction or a “biomarker” of NBIA remains to be determined [38].

**Inheritance and Gender**

Beta-propeller protein-associated neurodegeneration is inherited in an X-linked dominant manner, but the vast majority of cases (91.5% of the reported cases) are singletons due to de novo mutations. Most affected individuals are female, suggesting reduced survival of male embryos carrying pathogenic WDR45 mutations [18, 38]. The broad phenotypic variability in females can be at least partly explained by mosaicism due to skewed X chromosome inactivation. Disease severity in females ranges from pronounced and early disability to asymptomatic carriers. Therefore, cases should not be assumed to be de novo in the absence of clinical signs in the mother [27].
A few male patients have been described, and most seem to have similar but more severe disease [6, 16, 20, 27]. Evidence suggestive of somatic mosaicism (i.e., uneven distribution in different cells and tissues) was reported in one male patient [1] offering a potential explanation for the highly variable involvement and disease severity also seen in males. In conclusion, the broad spectrum of clinical features and severity of BPAN is believed to be due to a combination of one or more of the following: the severity of the mutation, skewed X chromosome inactivation in females, and somatic mosaicism in both sexes.

**Conclusion**

We have reviewed data from 68 published cases of BPAN. Our analyses show that the clinical spectrum of BPAN is highly heterogeneous. Next-generation, broad-spectrum genetic analyses, such as whole-exome sequencing, have enabled early detection of BPAN also in individuals with atypical phenotypes, rendering this disorder highly relevant for both pediatric and adult neurologists. Early diagnosis and regular clinical follow-up of patients with BPAN are essential in order to offer proper genetic counseling to the affected families, anticipate the deterioration that occurs later in the course of the disease, and provide symptomatic therapy for the movement disorder, when appropriate. The molecular pathophysiology of BPAN is only starting to become unraveled and provides an intriguing novel link between neurodegeneration and impaired autophagy. Increased insight into the molecular mechanisms underlying BPAN will enable the design of tailored therapies for this debilitating disorder and may also provide novel understanding into the role of autophagy in brain aging and neurodegeneration.

**Acknowledgments**

This work was supported by grants from the Regional Health Authority of Western Norway (Helse Vest, grants no 911903, 911988, and 911810).

**Authorship**

KES: conceived and designed the study, collected the data, performed statistical analyses, and drafted the manuscript. IOG: collected the data and drafted the manuscript. GH: collected the data and drafted the manuscript. PMK: collected the data and drafted the manuscript. CT: received funding, conceived and designed the study, collected the data, and drafted the manuscript.

**Conflict of Interest**

None declared.

**References**

1. Haack, T. B., P. Hogarth, M. C. Krueger, A. Gregory, T. Wieland, T. Schwarzmayr, et al. 2012. Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet. 91:1144–1149.

2. Hogarth, P. 2015. Neurodegeneration with brain iron accumulation: diagnosis and management. J. Mov. Disord. 8:1–13.

3. Gregory, A., M. A. Kurian, T. Haack, S. J. Hayflick, P. Hogarth. 1993. Beta-propeller protein-associated neurodegeneration. R. A. Pagon, et al., eds. GeneReviews (R). University of Washington, Seattle, WA.

4. Flones, I., P. Sztromwasser, K. Haugarvoll, C. Döble, M. Lykouri, T. Schwarzmüller, et al. 2016. Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. PLoS ONE 11: e0149055.

5. Long, M., N. Abdeen, M. T. Geraghty, P. Hogarth, S. Hayflick, and S. Venkatesswaran. 2015. Novel WDR45 mutation and pathognomonic BPAN imaging in a young female with mild cognitive delay. Pediatrics 136:e714–e717.

6. Nakashima, M., K. Takano, Y. Tsuyusaki, S. Yoshitomi, M. Shimono, Y. Aoki, et al. 2016. WDR45 mutations in three male patients with West syndrome. J. Hum. Genet. 61:653–661.

7. Khalifa, M., and L. Naffaa. 2015. Exome sequencing reveals a novel WDR45 frameshift mutation and inherited POLR3A heterozygous variants in a female with a complex phenotype and mixed brain MRI findings. Eur. J. Med. Genet. 58:381–386.

8. Wynn, D. P., and S. M. Pulst. 2017. A novel WDR45 mutation in a patient with beta-propeller protein-associated neurodegeneration. Neurol. Genet. 3:e124.

9. Okamoto, N., T. Ikeda, T. Hasegawa, Y. Yamamoto, K. Kawato, T. Komoto, et al. 2014. Early manifestations of BPAN in a pediatric patient. Am. J. Med. Genet. A 164A:3095–3099.

10. Tschentscher, A., G. Dekomien, S. Ross, K. Cremer, G. M. Kukuk, J. T. Epplen, et al. 2015. Analysis of the C19orf12 and WDR45 genes in patients with neurodegeneration with brain iron accumulation. J. Neurol. Sci. 349:105–109.

11. Van Goethem, G., J. H. Livingston, D. Warren, A. J. Oojageer, G. I. Rice, and Y. J. Crow. 2014. Basal ganglia calcification in a patient with beta-propeller protein-associated neurodegeneration. Pediatr. Neurol. 51:843–845.

12. Ryu, S. W., J. S. Kim, and S. H. Lee. 2015. Beta-propeller-protein-associated neurodegeneration: a case of mutation in WDR45. J. Clin. Neurol. 11:289–291.
13. Ozawa, T., R. Koide, Y. Nakata, H. Saitsu, N. Matsumoto, K. Takahashi, et al. 2014. A novel WDR45 mutation in a patient with static encephalopathy of childhood with neurodegeneration in adulthood (SENDA). Am. J. Med. Genet. A 164A:2388–2390.

14. Ichinose, Y., M. Miwa, A. Onohara, K. Obi, K. Shindo, H. Saitsu, et al. 2014. Characteristic MRI findings in beta-propeller protein-associated neurodegeneration (BPAN). Neurrol. Clin. Pract. 4:175–177.

15. Rathore, G. S., C. P. Schaaf, and A. J. Stocco. 2014. Novel mutation of the WDR45 gene causing beta-propeller protein-associated neurodegeneration. Mov. Disord. 29:574–575.

16. Abidi, A., C. Mignon-Ravix, P. Cacciagli, N. Girard, M. Milh, and L. Villard. 2016. Early-onset epileptic encephalopathy as the initial clinical presentation of WDR45 deletion in a male patient. Eur. J. Hum. Genet. 24:615–618.

17. Xixis, K. I., and M. A. Mikati. 2015. Epileptic spasms: a previously unreported manifestation of WDR45 gene mutation. Epileptic. Disord. 17:467–472.

18. Hayflick, S. J., M. C. Kruer, A. Gregory, T. B. Haack, M. A. Kurian, H. H. Houlden, et al. 2013. Beta-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 136:1708–1717.

19. Saitsu, H., T. Nishimura, K. Muramatsu, H. Kodera, S. Kumada, K. Sugai, et al. 2013. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 45:445–9. e1.

20. Spiegel, R., S. Shalev, D. Bercovich, D. Rabinovich, M. Khayat, A. Shaag, et al. 2016. Severe infantile male encephalopathy is a result of early post-zygotic WDR45 somatic mutation. Clin. Genet. 90:560–562.

21. Nishihoka, K., G. Oyama, H. Yoshino, Y. Li, T. Matsushima, C. Takeuchi, et al. 2004. High frequency of beta-propeller protein-associated neurodegeneration (BPAN) among patients with intellectual disability and young-onset parkinsonism. Neurobiol. Aging 2015(36):e9–e15.

22. Verhoeven, W. M., J. I. Egger, D. A. Kooiien, H. Yntema, S. Olgiati, G. J. Breedveld, et al. 2014. Beta-propeller protein-associated neurodegeneration (BPAN), a rare form of NBIA: novel mutations and neuropsychiatric phenotype in three adult patients. Parkinsonism Relat. Disord. 20:332–336.

23. Ohba, C., S. Nabatame, Y. Iijima, K. Nishiyama, Y. Tsurusaki, M. Nakashima, et al. 2014. De novo WDR45 mutation in a patient showing clinically Rett syndrome with childhood iron deposition in brain. J. Hum. Genet. 59:292–295.

24. Yoganathan, S., G. Arunachal, S. V. Sudhakar, V. Rajaraman, M. Thomas, and S. Danda. 2016. Beta propeller protein-associated neurodegeneration: a rare cause of infantile autistic regression and intracranial calcification. Neuropediatrics 47:123–127.

25. Hoffjan, S., A. Ibisier, A. Tschentscher, G. Dekomien, C. Bidinost, and A. L. Rosa. 2016. WDR45 mutations in Rett (-like) syndrome and developmental delay: case report and an appraisal of the literature. Mol. Cell. Probes 30:44–49.

26. Takano, K., N. Shiba, K. Wakui, T. Yamaguchi, N. Aida, Y. Inaba, et al. 2016. Elevation of neuron specific enolase and brain iron deposition on susceptibility-weighted imaging as diagnostic clues for beta-propeller protein-associated neurodegeneration in early childhood: additional case report and review of the literature. Am. J. Med. Genet. A 170A:322–328.

27. Zarate, Y. A., J. R. Jones, M. A. Jones, F. Millan, J. Juusola, A. Vertino-Bell, et al. 2016. Lessons from a pair of siblings with BPAN. Eur. J. Hum. Genet. 24:1080–1083.

28. Aminfeng, K. 2013. WDR45 mutations define a novel disease entity—static encephalopathy of childhood with neurodegeneration in adulthood. Clin. Genet. 84:209.

29. Paudel, R., A. Li, S. Wietthoff, R. Bandopadhyay, K. Bhatia, R. de Silva, et al. 2015. Neuropathology of Beta-propeller protein associated neurodegeneration (BPAN): a new tauopathy. Acta Neuropathol. Commun. 3:39.

30. Araújo, R., A. Garabal, M. Baptista, S. Carvalho, C. Pinho, J. de Sá, et al. 2017. Novel WDR45 mutation causing beta-propeller protein associated neurodegeneration (BPAN) in two monozygotic twins. J. Neurol. 264:1020–1022.

31. Morikawa, M., K. Takano, M. Motobayashi, N. Shiba, T. Kosho, Y. Nakazawa, et al. 2017. Clinical features of a female with WDR45 mutation complicated by infantile spasms: a case report and literature review. Brain Dev. 39:804–807.

32. Hattingen, E., N. Handke, K. Cremer, S. Hoffjan, and G. M. Kukuk. 2017. Clinical and imaging presentation of a patient with beta-propeller protein-associated neurodegeneration, a rare and sporadic form of Neurodegeneration with Brain Iron Accumulation (NBIA). Clin. Neuroradiol. 27:481–483.

33. Li, D., and R. Roberts. 2001. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell. Mol. Life Sci. 58:2085–2097.

34. Proikas-Cezanne, T., S. Waddell, A. Gaugel, T. Frickey, A. Lupas, and A. Nordheim. 2004. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. Oncogene 23:9325–9325.

35. Meyer, E., M. A. Kurian, and S. J. Hayflick. 2015. Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. Annu. Rev. Genomics Hum. Genet. 16:257–279.
36. Behrends, C., M. E. Sowa, S. P. Gygi, and J. W. Harper. 2010. Network organization of the human autophagy system. Nature 466:68–76.
37. Ebrahimi-Fakhari, D., A. Saffari, L. Wahlster, J. Lu, S. Byrne, G. F. Hoffmann, et al. 2016. Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism. Brain 139:317–337.
38. Horvath, R. 2013. Brain iron takes off: a new propeller protein links neurodegeneration with autophagy. Brain 136:1687–1691.